Wall Street brokerages expect that STRATA Skin Sciences Inc (NASDAQ:SSKN) will report sales of $7.64 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for STRATA Skin Sciences’ earnings, with the lowest sales estimate coming in at $7.60 million and the highest estimate coming in at $7.67 million. STRATA Skin Sciences posted sales of $7.48 million during the same quarter last year, which suggests a positive year-over-year growth rate of 2.1%. The company is expected to issue its next quarterly earnings report on Thursday, November 8th.
On average, analysts expect that STRATA Skin Sciences will report full-year sales of $29.70 million for the current fiscal year, with estimates ranging from $29.40 million to $30.00 million. For the next year, analysts forecast that the company will post sales of $34.15 million, with estimates ranging from $33.80 million to $34.50 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover STRATA Skin Sciences.
STRATA Skin Sciences (NASDAQ:SSKN) last announced its earnings results on Monday, August 13th. The medical device company reported ($0.02) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.01. STRATA Skin Sciences had a negative net margin of 63.07% and a negative return on equity of 27.01%. The business had revenue of $7.53 million during the quarter, compared to analysts’ expectations of $6.84 million.
SSKN stock traded down $0.24 during midday trading on Friday, reaching $2.92. 182,600 shares of the company’s stock traded hands, compared to its average volume of 209,323. STRATA Skin Sciences has a 52-week low of $1.06 and a 52-week high of $3.88. The stock has a market cap of $95.82 million, a P/E ratio of 1.64 and a beta of 0.58. The company has a current ratio of 4.77, a quick ratio of 4.20 and a debt-to-equity ratio of 0.22.
Hedge funds have recently made changes to their positions in the business. Nantahala Capital Management LLC purchased a new stake in shares of STRATA Skin Sciences in the second quarter worth $4,261,000. Menora Mivtachim Holdings LTD. purchased a new stake in shares of STRATA Skin Sciences in the second quarter worth $1,138,000. Renaissance Technologies LLC increased its stake in shares of STRATA Skin Sciences by 164.6% in the second quarter. Renaissance Technologies LLC now owns 293,499 shares of the medical device company’s stock worth $602,000 after purchasing an additional 182,579 shares in the last quarter. Finally, Macquarie Group Ltd. increased its stake in shares of STRATA Skin Sciences by 89.7% in the second quarter. Macquarie Group Ltd. now owns 134,033 shares of the medical device company’s stock worth $275,000 after purchasing an additional 63,393 shares in the last quarter. 27.41% of the stock is owned by institutional investors and hedge funds.
STRATA Skin Sciences Company Profile
STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.
Further Reading: What is a Call Option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.